

Ultraviolet-absorbing organic anions in uremic serum separated by capillary zone electrophoresis, and quantification of hippuric acid

Citation for published version (APA):

Schoots, A. C., Verheggen, T. P. E. M., Vries, de, P. M. J. M., & Everaerts, F. M. (1990). Ultraviolet-absorbing organic anions in uremic serum separated by capillary zone electrophoresis, and quantification of hippuric acid. Clinical Chemistry, 36(3), 435-440.

Document status and date:

Published: 01/01/1990

Document Version:

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.

• The final author version and the galley proof are versions of the publication after peer review.

• The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](https://research.tue.nl/en/publications/dc33012d-2221-4770-b276-78e94ec05e9c)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
	- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.

Ultraviolet-Absorbing Organic Anions in Uremic Serum Separated by Capillary Zone Electrophoresis, and Quantification of Hippuric Acid

A. C. Schoots,1 **T. P. E. M.** Verheggen,' **P. M. J. M. De Vrles,2 and F. M. Everaerts1**

Organic anions accumulated in blood serum of patients with chronic renal failure were separated by a novel technique: closed-system capillary zone **electrophoresis (CZE)** in a pH 6 **carrier-electrolyte system. Hippuric** acid (HA), **p-hydroxyhippuric acid,** and uric acid were **identified** by **their co-elution with standards prepared in ultrafiltered normal serum and by comparison with the corresponding ultraviolet-detected** peaks **positively identified in the HPLC analyses. Analysis time for the entire profile is 8 mirt. Repeatabilities (CVs) of** CZE **migration times** and **peak areas of the three acids in serum samples were about 0.7% and 6%, respectively. We quantified** HA in 10 **ultrafiltered** uremic serum samples and **compared results with those** by a **previously described** HPLC procedure. The very good agreement **further supports the** identification of hippuric acid. Accuracy and precision of the CZE method were **similar to those for the** HPLC **gradient**elution method, but analysis time for HA (8 min) is much less than by HPLC (90 min). Our technique is very suitable for selective, rapid analysis for (ultraviolet-absorbing) **anionic** constituents in ultrafiltered uremic serum, without any sample pretreatment.

Additional Keyphrases: renal function · tubular secretion anion gap · uremic toxins · HPLC compared · solvent effect

Substances that accumulate in the body fluids **of patients with advanced impairment of renal function include aro matic or indolic compounds (e.g., phenols, phenolic acids, hippurates, indolic acids, amines), heterocyclic nitrogencontaining compounds (e.g., guanidines, creatiine,** uric **acid), trace elements (e.g., aluminum, nickel), low-molecu-** α **lar-mass** proteins (e.g., β_2 -microglobulin, lysozyme, retinol**binding protein), parathyrin, potassium, and** so-called middle **molecules** *(1-4).*

Artificial methods for blood purification such as hemedialysis and **continuous ambulatory** peritoneal dialysis partly suppress or prevent the clinical symptoms observed **in patients with advanced renal failure. Therefore, dialyzable toxins apparently must be** directly **or indirectly re sponsible for the multiple disorders observed in uremic** patients. Until now, there has been no conclusive evidence **for the toxicity of a single substance or a specific group of** accumulating solutes. For the past 15 years, much attention has been paid to the "middle molecule" hypothesis *(5),* but this hypothesis is not convincingly supported by experimental **evidence, partly** because **the "middle molecules"** are ill-defined chemically *(3, 6).*

Various authors **have pointed out the potential** impor-

tance **of organic anions that** normally **are excreted into** urine by a highly efficient (proximal) tubular secretory mechanism in the kidney *(7-9).* These solutes inhibit cell-membrane ion transport in various tissues *(8, 10).* **Recently, a multivariate statistical study showed that high** conduction velocities in patients on maintenance dialysis *(11).* Hippuric **acid (HA), the aromatic acid regularly present at the highest concentration in uremic serum, may** account **for** part **of the positive anion-gap** *(12)* **observed in uremic patients** and **has** been shown to inhibit drug**protein binding in (dialyzed) renal patients** *(13, 14).* **Hip**purates **are glycine conjugates formed in the liver from** benzoic acids. Benzoic **acid** originates from **the diet (fruits and vegetables,** food preservatives), from mitochondrial **p-oxidation of phenyl-fatty acids** with **an odd number of** carbons, **and** from **oxidative breakdown of phenylalanine** through bacterial **action in the** intestines *(10, 15, 16).* Furthermore, environmental **contact with xylenes or tolu** enes results **in** increased **HA concentrations in serum. Commercial heparin, frequently** used **in hemodialysis practice, may contain benzyl alcohol, the metabolism of which results in the generation of HA.** Because HA may be a **marker of accumulation of tubularly** secreted organic acids (both **endogenous and exogenous) and their glycine conjugates in the serum, it is important to develop reliable, rapid methods for detection and quantification of HA and other aromatic acids.**

Organic acids in uremic serum **can be analyzed, as a** group, by use **of temperature-programmed** gas **chromatography** *(17, 18)* **or** "high-performance" liquid chromatography (HPLC) with gradient-elution *(9,19-21),* **both of which are relatively time-consuming procedures. Specific analysis for HA has also** been **done colorimetrically** *(22)* and **by** HPLC *(23),* **but these methods** require **sample** pretreat**ment, such as** extraction **with organic solvents. Other** methods **used for selective isolation of** urinary organic acids in general are anion-exchange and adsorption **chromatography** *(24).* **Earlier we** reported a preliminary **study** on the pre-separation of those anions present in uremic serum by isotachophoresis preceding HPLC *(25).* **Here we** describe a **method for the rapid assay of** anionic **constitu**ents in uremic serum by closed-system capillary zone electrophoresis (CZE), without sample pretreatment, and we compare results with those obtained with our HPLC method.

Materials and Methods

Serum and standard samples. Pre-dialysis blood, sam **pled from patients undergoing** regular hemodialysis **treat**ment, was allowed to clot before centrifugation, then stored at -70 °C until assay. Before analysis, the samples were deproteinized by centrifugal ultrafiltration (ambient **tem**perature, $1500 \times g$) through micropartition ultrafiltration units (Grace & **Co.,** Amicon **Div., Danvers, MA 01923).** Thus, the HA concentrations measured represent the por**tion of HA not bound to** serum **proteins [36% of HA in**

¹ Faculty of Chemical Engineering, SH2.05, Eindhoven University of Technology, P.O. Box **513, 5600** MB Eindhoven, The **Netherlands.**

² Department of Internal Medicine, Renal Unit, Free University Hospital, Amsterdam, The Netherlands.

Received October 23, 1989; accepted December 4, 1989.

uremic serum is protein-bound *(21)].* **We prepared** standard **solutions for calibration in CZE and HPLC by adding HA to ultrafiltered normal (nonuremic) reference serum to** give final concentrations in the injected calibration solutions **of** 0, 12.5, 25, 50, and 125 μ mol/L for CZE analysis and 0, 25, 50, 100, and 250 μ mol/L for HPLC analysis. Before injection, **the ultrafiltered normal** serum in these solutions was **diluted 10-fold for CZE, fivefold for HPLC. These same dilution factors were** used **with the** ultrafiltered uremic sera.

Capillary electrophoresis. **For** zone-electrophoresis exper**iments we** used a **home-made apparatus,** described in detail **elsewhere** *(26).* **The** sampling **unit has a fixed-volume (0.6** μ L) sampling compartment. For the separation compartment we used non-coated Teflon capillaries $(200 \mu m \text{ i.d.})$. **The** electrode compartments were separated from **the** sep**aration** compartment by semipermeable membranes. We used a slightly modified Model UV-M (Pharmacia, Upp**sala, Sweden)** fixed-wavelength ultraviolet-absorbance **de**tector, operated **at** 254 nm. During **analysis, the** electrical current **was kept constant at 50 or 35** *pA* and **the voltage at about 10 kV. An** Alpha-Series **power supply (Brandenburg,** Thornton **Heath, U.K.) was** used. Two carrier electrolyte systems **were used (Table 1).**

HPLC analyses were **performed as** described earlier *(9, 21)* **but with a different separation** column. **We used a** 4.6 mm **(i.d.)** *x* **25 cm Ultrasphere** Octadecyl (C18-modified $silica$) column, packed with $5-\mu m$ particles, in conjunction with a 2 mm $(i.d.) \times 3$ cm Ultrasphere Octadecyl guard column, packed with 10- μ m particles (both from Beckman Instruments Inc., Fullerton, CA). The 45-min solvent gra**dient was linear** from **100% aqueous** ammonium formate buffer **(0.05** moJL, **pH 4) to** 60% methanoll40% buffer. **The flow rate was 1** mL/min. **The separation** column **and the** solvent were kept **at 25 #{176}C by** means **of a** thermostated **bath and** column **water jacket. The** chromatograph consisted **of a** Model 421 **controller, two** Model 100A double-piston **pumps, a Model** 160 fixed-wavelength detector (wavelength **254 nm, range 0.02** *A* full scale), and a Model 500 autosam**pier (all from Beckman** Instruments). **The injection volume was 25** p.L.

Data acquisition and statistics. Zone-electrophoresis **elution profiles and HPLC** chromatograms **were** acquired with **a chromatography data system. We used a** Model 761S data interface **and Model 2600 chromatography software (both from Perkin-Elmer/Nelson,** Cupertino, **CA)** and an **IBM** PC/XT computer. Sampling frequency **was 10 Hz in** CZE and **1 Hz in** HPLC. For regression analysis we used **the** REG procedure **from** SAS statistical software *(27).*

Materials. 2-(N-Morpholino)ethanesulfonic acid and hip-

^a Teflon,0.2 mm (id.). MES, tonic acid. **MHEC, methylhydroxyethylcellutose.**

puric **acid were** obtained from Sigma Chemical **Co., St.** Louis, **MO 63178.Uric acid was** from Merck AG, Darmstadt, **F.R.G. We** synthesized p-hydroxyhippuric **acid by an** active-ester **method** *(28).* Normal reference sera (Precinorm; Boehringer Mannheim, Mannheim, **F.R.G.)** were used for preparing **the calibration solutions.** Methylhydroxyethylcellulose (Serva, Heidelberg, F.R.G.) was used as a surface-active **agent. For gradient-elution, we** used "HPLC**grade" methanol (FSA** Laboratory **Supplies, Loughborough, U.K.).** De-mineralized water **was obtained** with **a** Milli-Q water-purification system (Millipore/Waters, **El** Paso, TX 79998). Teflon capillaries [500 μ m (o.d.), 300 μ m (i.d.)J, were from **Habia, Breda, The Netherlands,** and were drawn **over an** inserted **copper wire** having an outer **diam** eter of 200 μ m to give the desired inner diameter.

Resufts and Discussion

Characteristics of the CZE Profiles

Analytical zone electrophoresis **in Teflon capillaries without electro-osmotic flow** was introduced **by** Mikkers and **colleagues** *(29, 30).* **Later on, Jorgenson** and Lukacs (31) used borosilicate glass capillaries $(75 \mu m)$ i.d.) and electro-osmotic **flow in their separations.** Recently, **gel**filled capillary columns were used *(32)* **to** separate **biomolecules,** exploiting sieving effects.

In our experiments, zone electrophoresis was performed as **we have** described. **We added** methylhydroxyethylcellulose to **the** carrier electrolytes **and used an apparatus in which the Teflon capillary** was separated from **the electrode** vessels **by** supported membranes, **to suppress** electro-os**motic** effects. **The ratio of zone** electrophoretic and electroosmotic velocity can be expressed **as follows:**

$$
\frac{\nu_{\text{ze}}}{\nu_{\text{eo}}} = -\frac{\epsilon \cdot \zeta}{\eta \cdot \mu}
$$

where ϵ is the dielectric constant, ζ the zeta-potential at the capillary surface, η the dynamic viscosity, and μ the ionic mobility. If we assume a value of approximately -1 mV for the ζ -potential at the Teflon surface in a pH 6 buffer system [a value measured earlier *(33),* for the analogous component hydroxyethylcellulose], we can calculate that the electroendosmotic "velocity," $\nu_{\rm so}$, is only 1% of the zoneelectrophoretic velocity, ν_{xx} . Hence, electroendosmosis would not be expected to influence the performance of the CZE analysis.

Uremic sera and standard solutions were analyzed by **CZE** and HPLC. Figure 1 shows zone electropherograms of **a** uremic serum ultrafiltrate analyzed **in** operational **Sys***tem* **^I (pH 3.8)** (Figure IA) **and in System H (pH 6) (Figure** IB) (see Table 1). In addition, the proffle **of an** ultrafiltered normal serum, analyzed **in System II, is** shown (Figure 1C). In System I, with a low pH (3.8) of the carrier electrolyte, **the weak** organic acids **in ultraflltered** uremic serum mi**grate much slower** than **in** System **II (pH 6).** Uric **acid (pK** ⁼ **3.89) did notpass the** detector in a reasonable time (i.e., 20 min) in this system, but was analyzed adequately in System **II. The** chromatogram **shows** that uric **acid** determination **in** human **sera by** CZE **is** promising. **We have** chosen **the fast system shown in** Figure 1B, **to** obtain a **more complete anionic** serum **proffle.**Figure 2 **shows the zone electropherogram and corresponding liquid chromato**gram **of an** ultrafiltered uremic serum sample. Peaks **tentatively** identified **in the figure legend were** obtained

Fig. 1. Capillary zone electropherograms of (A) **uremic serum in pH 3.8 electrolyte (System I, Table 1),** (B) **uremic serum in pH 6 electrolyte (System II, Table 1), and** (C) **ultraflltered normal** serum **in** pH 6 carrier electrolyte (System II, Table 1)

Tentativepeak **identifications:** 1, hippuric acid; Z **p-hydroxyhippunc acid;** 3, uric acid. Detection was at 254 nm. Ultrafiltered serum was diluted 1:1 with about
water in A, 1:8 in B and C. "AU" is A, absorbance

Fig. 2. Corresponding CZE and HPLC profiles for uremic serum **ultrafiltrates**

CZE analysis was done in System II (Table 1). Peak identifications common to both CZE and HPLC profile (tentatively in CZE) same as in Fig. 1. Other
neutral or cationic compounds in HPLC: a, creatinine; b, pseudouridine; *c,* hypoxanthine. Note differences of ordinate scale and injection volumes (0.6 μ L \overline{L} **in** CZE, 25 μ L in HPLC)

through co-elution of standards in CZE and, as reported **earlier, by** mass spectrometry and enzymatic peak shift **in** HPLC (4). Identification of the three prominent CZE peaks was supported by comparison with the prominent HPLC peaks, which were all detected at 254 nm.HA was eluted at $t_m = 5$ min in CZE and $t_R = 20$ min in HPLC. Total analysis time for the profiles is 8 min in CZE and 90 min in HPLC. The length of the latter is due to the necessity of re equilibrating the HPLC column after gradient development, before the next sample is injected. It should be noted, however, that in the HPLC profile, neutral, anionic, and cationic constituents of serum are measured simultaneously, whereas CZE selectively separates anionic substances under the present conditions-which is desirable, because earlier studies *(8)* have shown that especially the group of tubularly secreted organic anions may be of importance in the etiology of uremic **manifestations.**

The CZE proffles show a large, asymmetrical negative peak starting at migration time of about 1.5 min, which originates from the large amount of Cl^- ions present in serum. Chloride is eluted as the first component because of its high absolute mobility of 80 \times 10⁻⁵ cm²/V·s. Its concentration ordinarily is 110 mmol/L in serum water and varies only to a minor extent among most patients. This

fact is of importance **for the reproducibility of migration** times. The presence of a major component in the injected sample may significantly influence migration times, as is **illustrated** in Figure 3. The electropherograms represent the analyses **of** diluted ultrafiltered **sera to which different** amounts **of** sodium chloride **were added. The greater the** amount **of chloride added, the longer the migration times of** the **(other) sample constituents, the smaller their (diffusive) dispersion, and the closer their relative migration** distances. Serum components eluting closely after **the back edge of the** chloride zone are very sharp, **and peak-shape** analysis, based **on** statistical **moments, demonstrates the**oretical plate numbers *(34)* **of >1 000000 for these com** pounds. **Plate** numbers measured **for** low-molecular-mass solutes, injected **in the absence of a major component, are about 30000** *(26).* **We** calculated **that the plate number** decreases rapidly with **elution time for** peaks **eluting** after **the chloride zone. This delayed elution phenomenonwhich is related to the** sample **composition upon injection** and **which is analogous to the "solvent effect" observed in** gel filtration and in gas and liquid chromatography *(35-* 38)-will be described **elsewhere in more detail** (Schoots **et** al., ma. submitted **for publication).** Peak **heights of the minor components are higher when** the amount **of chloride** added is greater (Figure **3).** This "solvent effect," **as ex** pected, can be used **to** enhance detectability **of** specific **(minor)** sample constituents **by adding a major component**

Fig. 3. Zone electropherograms (in System II; Table 1) of a 40 fold-diluted ultrafiltered **uremic serum sample with different amounts of** sodium chloride added: (top) **2.8 mmol/L (no Cl added),** (middle) **13.2 mmol/L,** (bottom) 54.4 **mmol/L**

Tentativepeakidentificationssame as in Fig. **1**

of appropriate nature **and concentration.**

The elution order for uric acid, p-hydroxyhippuric **acid,** and HA is reversed in CZE as compared with reversed**phase** HPLC. **In** HPLC, under **the given conditions** (C18 modified silica, **eluent pH 4) where the weak organic** acids **are** only partly dissociated, **the hydrophobic character of** the solutes seems to determine the elution order: $t_{\text{R,UA}}$ < $t_{\text{R,PHHA}} < t_{\text{R,HA}}$. In the CZE experiments the following order **of** increasing effective **ionic mobility was found for the three organic acids, as** analyzed **in** ultrafiltered serum: $\mu_{\text{UA}} < \mu_{\text{PHHA}} < \mu_{\text{HA}}$. The pK values (2.700, charge -1; **7.27 1, charge -2) and corresponding absolute mobilities** $(25.3 \times 10^{-5} \text{ and } 55.1 \cdot 10^{-5} \text{ cm}^2/\text{V} \cdot \text{s},$ respectively) of HA $(25.3 \times 10^{-5} \text{ and } 55.1 \cdot 10^{-5} \text{ cm}^2/\text{V} \cdot \text{s}$, respectively) of HA
have been reported by Hirokawa et al. (39). The first pK
value, 2.7, is lower than the value reported (pK = 3.8) in
another publication (40). Effect value, 2.7, is lower than the value reported $(pK = 3.8)$ in **another publication** *(40).* Effective mobility, as is expressed **in migration time, depends on several** factors **such as effective molecular radius, pK value,** and concentration or activity coefficient. Moreover, secondary equilibria **such as complexation influence** effective mobility and thus **migration time. Therefore, the discrepancy** between reported plC **values** cannot **be judged** from **the** present data **for serum** samples; measurements under standardized conditions are necessary *(41).*

Table 2 shows the repeatability (CVs) of migration times and peak areas in CZE of three components in uremic serum. At other concentrations these data are similar. **Similar data have** been reported **earlier for the gradient** HPLC analysis *(20),* **the CVs being 0.6-1.0%** and 3-6% **for retention times and peak heights,** respectively.

HA was assayed **in** various concentrations in the series of **ultrafiltered uremic serum samples,**and **the CV for its** migration time in **CZE was 2.5% (n ⁼ 20, all** samples run **on the same day).**

Quantification

HA was quantified in 10 samples of ultraiiltered serum **from uremic patients who were undergoing hemodialysis. The ultrafiltered serum samples were diluted 10-fold before injection in the CZE procedure. The samples were all analyzed during one day, and calibration solutions were placed in between them. Peak** area **depends on migration velocity, because ultraviolet absorbance is a concentrationdependent detection principle. Therefore, in quantitative** analysis based **on peak area we** used **a constant** electrical current, $35 \mu A$, in all experiments. Quantification of HA by **CZE was** compared **with quantification by HPLC, in which** samples **were** diluted **fivefold before** injection. Injected amounts were 0.6 μ L in CZE, 25 μ L in HPLC-the latter being injected via **an autosampler. For** calibration, standard **solutions were prepared by addition ofHA to** ultrafiltered normal serum **(see** *Materials and Methods).* Peak **height is not linearly related to concentration in** CZE under

Table 2. RepeatabilIty of Migration Times, Peak Areas, **and** Peak **Heights of Hippuric Acid, p-Hydroxyhippuric Acid, and Uric Acid In Uftrafiltered Uremic Sera (n ⁼ 5)**

Component	Mean migration time, min	Migration time	Peak height	Peak area
		CV. %		
Hippuric acid	5.07	0.86	4.9	6.4
p-Hydroxyhippuric acid	5.35	0.77	7.4	5.5
Uric acid	5.88	0.73	4.5	6.5

the present conditions, because solute peaks are intrinsically asymmetrical **in CZE at these concentrations (i.e., >1** molJL) *(30).* **The HA concentration range of the** injected calibration solutions was 0 to $125 \mu \text{mol/L}$. Although CZE peaks were asymmetrical **at these concentrations, this does not** influence peak *area* **as long as sufficient resolution** from

migration **Fig. 4. Method** comparison of quantification of **HA in CZE** and **HPLC**

(top) and by HPLC peak height (middle)
Bottom: Abecissa and ordinate values were the mean of duplicate measure-
ments in both CZE and HPLC, and are calculated as the concentrations in undiluted ultrafiltered uremic sera. Top and middle: HA was added to normal reference serum **other** sample components is maintained. **Therefore, HA concentrations** up to 1250 μ mol/L in ultrafiltered uremic **serum can be** measured because, **in CZE, samples were** diluted **10-fold before** injection. Peak **height has been found** to be more reproducible than peak area in HPLC analysis (20). **Therefore,** peak *area* is used **in** CZE **and peak** *height* **in** HPLC. **Calibration curves for HA in CZE and HPLC were** obtained **by injecting the calibration solutions in duplicate.**

A linear **model was** fitted **to the calibration data for HA,** yielding **the following relations:**

CZE: Area_{HA} = $437 + 174 \cdot (concentration_{HA})$;

 $r = 0.999 (P \le 0.0001)$.

HPLC: Height_{HA} = $-481 + 60.83 \cdot (concentration_{HA})$; *r* **⁼ 0.999** *(P* <0.0001).

The y-axis intercepts **were not significantly different** from zero (by t-test) in either **CZE** and HPLC.

We compared the present CZE technique with HPLC (9, *21),* **with** respect to **quantification of** HA. Figure 4 **shows the outcome of this comparative study. The ultrafiltered** serum samples were analyzed **in duplicate** both in **CZE and in HPLC, and the data** points represent mean values for **these** determinations. **We found a** good agreement **for the** quantification **of HA. The regression line** shown **in** Figure **4** follows the equation $\text{Concn}_{\text{HACZE}} = -35.16 + \frac{13}{\text{ind}}$ $1.0860 \cdot (Concn_{HALHPLC}); r = 0.981 (P < 0.0001).$

The y-axis intercept was **not** significantly different from zero $(t = -1.475, P = 0.18)$, nor was the slope of the **regression line (1.086) significantly different** from unity *(F* $= 1.29, P = 0.29.$

Conclusion

The present study demonstrates the reliability of a new, rapid, and selective **method of analysis for ultraviolet**absorbing anionic constituents—especially HA—in uremic serum **by CZE. The separation,** based **on** differences **in** electrophoretic **mobility of the** anionic sample constituents, is therefore very suitable for the analysis of these types of compounds **in** uremic serum. HA, **which is prominently** present in uremic serum, can be **quantified as** accurately and **precisely as with HPLC.** Our method **will facilitate the** study **of the usefulness of HA as a marker of accumulation of tubularly secreted organic acids and of its role in drugprotein binding in patients with chronic renal failure. The** "solvent effect" we observed when there is a major compo**nent** (chloride) **in the injected sample may be useful for** enhancing **the** detectability **of minor components. Cur**rently, commercial **CZE equipment is available** that **en ables** organic acids **in** uremic serum to be **resolved with even higher efficiency by use of** separation capillaries **with** internal diameters of $75 \mu m$ (or less) and involving electroosmotic **flow** *(42).*

References

1. Wills MR. Uremic toxins, and **their effect on** intermediary **metabolism [Review]. Clin Chem 1985;31:5-13.**

2. &hreiner GE, Maher **JF. Uremia: biochemistry, pathogenesis,** and treatment [Review]. Springfield, IL: Charles C **Thomas,** 1961:55-232.

3. Schoots A, Mikkers F, Cramers C, De Smet R, Ringoir S. Uremic toxins and the elusive middle molecules. Nephron 1984;38:1-8.

4. Schoots AC.Multicomponent analysis of accumulated solutes **in** uremia **[Dissertation]. Eindhoven University of** Technology, **Eindhoven, The Netherlands,** 1988.

5. Babb AL, Farrell PC, **Uvelli DA,** Scribner **BH.** Hemodia1yzer evaluation **by** examination of solute molecular spectra. Trans Am Soc Artif Intern Organs **1972;28:98-105.**

6. Schoots **AC, Mikkers FEP, Claessens HA, De Smet R,** Van Landschoot **N, Ringoir SMG. Characterization of** uremic **"middle molecular" fractions by** gas **chromatography,** mass spectrometry, isotachophoresis, **and liquid chromatography. Clin Chem 1982;** 28:45-9.

7. Smith **HW, Finkelstein N, Aliminosa L,**Crawford B,**Graber M. The renal** clearances of substituted hippuric acid derivatives and **other aromatic acids in dog and man. J Clin Invest 1945;24:388-** 404.

8. Grantham JJ, Whittier F, Diederich D. Uremia: strategies in **the** search for toxins. **In:** Andreoli TE, Hoffman **JF,** Fanestil **DD,** eds. Physiology of membrane disorders. New York: Plenum, 1978: 955-65.

9. Schoots **AC,** Dijkstra **JB,** Ringoir **SMG, Vanholder R,** Cramers **CA. Are the** classical markers sufficient **to** describe uremic **solute** accumulation in dialyzed patients? Hippurates reconsidered. Clin **Chem 1988;34:1022-9.**

10. Bourke E, Frindt G, Preuss H, Rose E, Weksler M, Schreiner GE.Studies with uraemic serum **on the renal** transport **of hippu**rates **and** tetraethylammonium in the rabbit and rat: effects of oral neomycin. Clin Sci 1970;38:41-8.

11. Schoots **AC, De** Vries PMJM, Thiemann R, et al. Biochemical **and** neurophysiological parameters **in** dialyzed **patients** with chronic renal failure. Clin Chim Acta**1989;185:91-108.**

12. Gabow PA. Disorders associated **with an** altered anion gap. **Kidney** mt **1985;27:472-83.**

13. Gulyassy PF, Jarrard **E, Stanfel L. Contributions of hippurate, indoxyl sulfate, and o-hydroxyhippurate to** impaired **ligand binding by plasma in** azotemic humans. Biochem Pharmacol **1987;36:4215-20.**

14. Vanholder R, Van Landschoot N, **De Smet R,** Schoots A, Ringoir **S. Drug protein binding in** chrome renal failure: evalua**tion of nine drugs. Kidney** mt **1988;33:996-1004.**

15. Stryer **L. Biochemistry, 2nd ed. New York, NY: WH** Freeman **and Co., 1981:387 pp.**

16. West ES, Todd WR, Mason **HS, Van Bruggen JT, eds.** Textbook of biochemistry. **New York, NY: Macmillan Co., 1966:1453 pp.**

17. Niwa T. Metabolic proffling with gas chromatography-mass spectrometry **and its** application to **clinical medicine. J** Chromatogr 1986;379:313-45.

18. Liebich HM, Pickert **A,** Tetachner B. Gas chromatographic **and** gas chromatographic-mass spectrometric **analysis of organic acids in plasma of patients with** chronic renal failure. *J* Chromatogr 1984;289:259-66.

19. Senftleber **FC,** Halline **AG,** Veening H, Dayton **DA.** Reversedphase liquid chromatographic **analysis of hemodialysate** from **uremic patients. Clin Chem 1976;22:1522-7.**

20. Schoots **AC,** Homan **HR, Gladdines MM,** Cramers **CA, De Smet R, Ringoir S. Screening of** UV-absorbing solutes in uremic serum **by** reversed-phase HPLC. Change **of** blood **levels** in **different** therapies. Clin Chim Acta 1985;146:37-51.

21. Schoots **AC, Gerlag P,Mulder AW,** Peeters JAG, Cramers CAMG. **Liquid-chromatographic profiling of** uremic solutes in serum of patients undergoing hemodialysis and chronic **ambula**tory peritoneal dialysis (CAPD); high concentrations of pseudouridine in CAPD**patients.** Clin Chem 1988;34:91-7.

22. Ohmori S, Ikeda M, Kira S, Ogata **M.Colorimetric determination of** hippuric **acid** in urine **and liver homogenates.** Anal **Chem 1977;49:1494-6.**

23. Igarishi P, Gulyassy P,Stanfel **L, Depner T.Plasma hippurate in renal failure: high** performance **liquid chromatography method** and clinical **application.** Nephron 1987;47:290-4.

24. Grater J, Jacobson CE. Urinary organic acids; isolation and **quantification for routine metabolic screening. Clin Chem** 1987;33:473-80.

25. Schoots AC, Everaerts FM. Isotachophoresis as a preseparation technique for liquid chromatography. J Chromatogr 1983;277:328-32.

26. Verheggen TPEM, Schoots **AC,** Everaerta FM. Feasibility of closed-system capillary zone electrophoresis. J Chromatogr (In press).

27. SAS/STAT guide for personal computers, Version *6* edition. Cary, NC: SAS **Institute Inc., 1985.**

28. Van Brussel W, Van Summere C. N-Acylamino acids and peptides VI. A simple synthesis of N-acylglycines of the benzoyl**and cinnamoyl-type. Bull Soc** Chim Beig **1978;87:791-7.**

29. Mikkers **FEP,** Everaerts FM, **Verheggen** TPEM. Concentration distributions in free zone electrophoresis. **J** Chromatogr 1979;169:1-1O.

30. Mikkers FEP. Isotachophoresis and zone electrophoresis in narrow-bore tubes [Dissertation]. Eindhoven University of Technology, Eindhoven, The Netherlands, 1980.

31. Jorgenson JW, Lukacs KD. High-resolution separations based on electrophoresis and electroosmosis. J Chromatogr 1981; 218:209-16.

32. Karger BL, Cohen AS, Guttman A. High performance capillary electrophoresis in **the** biological sciences [Review]. **J** Chromatogr 1989;492:585-614.

33. Reijenga JC, Aben GVA, Verheggen TPEM, Everaerts FM. Effect of electroosmosis on detection in isotachophoresis. J Chromatogr 1983;260:241-54.

34. Giddings **JC. Generation of**variance, "theoretical plates," resolution, and peak capacity in electrophoresis **and** sedimentation. Sep Sci **1969;4:181-9.**

35. Beling CG.Factors influencing the gel filtration **of** conjugated oestrogens. Acts Endocrinol 1963;43(Suppl 79):22-36.

36. Deans DR. The sample as **its** own stationary phase in gas chromatography. Anal **Chem 197 1;43:2026-9.**

37. Grob K. On-column injection in capillary gas chromatography. Basic technique, retention gaps, solvent effects. Heidelberg: Huthig Verlag, 1987:245-355.

38. Kraak JC,Smedes F, Meijer JWA. Application of on-column concentration of deproteinized serum **to** the HPLC determination of anticonvulsants. Chromatographia 1980;13:673-6.

39. Hirokawa T, Nishino M, Aoki N, et al. Table of isotachophoretic indices. I. Simulated **qualitative and quantitative indices** of 207 anionic substances in the range pH **⁼** 3-10. J Chromatogr **1983;271:1-106.**

40. Weast RC, Astle MJ, eds. CRC handbook of chemistry and physics, **62nd ed.** Boca Raton, **FL: CRC Press, 1981:D142-3.**

41. Beckers **JL.** Determination **of** absolute mobilities **and plCvalues by** isotachophoresis. **J** Chromatogr 1984;320:147-58.

42. Schoots AC, Koomen **aCM,** Everaerts FM, Arias L. High**resolution separations by capillary zone electrophoresis of accumulated** solutes **in** body **fluids of patients with** (chronic) renal failure [Abstract]. **2nd** Int. Symp. **on** High Performance Capillary Electrophoresis, San Francisco, Jan. 29-31 (In press).